Share on LinkedInShare on LinkedIn

ARTICLE · 02 AUGUST 2009

OFT Publishes Glaxosmithkline/Pfizer HIV Collaboration Decision

Following its decision not to refer the anticipated joint venture between GlaxoSmithKline plc ("Glaxo") and Pfizer Inc ("Pfizer") to the Competition Commission on 9 July 2009, the OFT has published the full text of its decision.

United KingdomAntitrust/Competition Law
SJ Berwin'S EU & Competition Team
SJ Berwin'S EU & Competition Team

Following its decision not to refer the anticipated joint venture between GlaxoSmithKline plc ("Glaxo") and Pfizer Inc ("Pfizer") to the Competition Commission on 9 July 2009, the OFT has published the full text of its decision.

The proposed transaction will see Glaxo and Pfizer pool the entirety of their businesses for HIV treatment into a joint venture company ("JV") (with Glaxo having a controlling interest and Pfizer a material influence). The JV will focus solely on the research, development and commercialisation of HIV treatments - giving it a share of supply of between 20% and 30% by value in the HIV market, and triggering review under the Enterprise Act.

In assessing the proposed merger, the OFT considered the appropriate frame of reference: it considered fragmenting the market for those HIV drugs that were already marketed and those that were still in the pipeline, but, as the deal raised no serious competition concerns either way, the OFT did not conclude

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from